AXIOS August 8, 2024
Eli Lilly proved Thursday that the market for weight-loss drugs isn’t softening.
Why it matters: The company is riding the GLP-1 rocket ship to higher sales and profits, cementing its status as a global pharmaceutical powerhouse.
The big picture: Lilly’s rival, Ozempic and Wegovy maker Novo Nordisk, generated concern Wednesday when it cut its full-year profit outlook on the back of disappointing quarterly sales.
- Questions emerged as to whether the market for anti-diabetes and obesity drugs could be showing early signs of cracking.
- Lilly Thursday erased those fears.
Driving the news: The Indianapolis-based drug giant raised its sales forecast after crushing revenue expectations for its most critical treatments.
- Sales of weight-loss drug Zepbound totaled $1.24 billion in...
Today's Sponsors
Today's Sponsor